LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

Search

AnaptysBio Inc

Slēgts

SektorsVeselības aprūpe

20.15 1.1

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

19.92

Max

20.2

Galvenie mērījumi

By Trading Economics

Ienākumi

699K

-39M

Pārdošana

-5.5M

22M

Peļņas marža

-173.517

Darbinieki

136

EBITDA

9.2M

-18M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+119.91% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 3. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-152M

559M

Iepriekšējā atvēršanas cena

19.05

Iepriekšējā slēgšanas cena

20.15

Ziņu noskaņojums

By Acuity

41%

59%

129 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

AnaptysBio Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 15. aug. 16:11 UTC

Galvenie tirgus virzītāji

Health Insurers Climb as Berkshire Hathaway Takes UnitedHealth Stake

2025. g. 15. aug. 22:22 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 15. aug. 22:22 UTC

Tirgus saruna

Target Is Falling Behind Its Peers -- Market Talk

2025. g. 15. aug. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 15. aug. 20:33 UTC

Tirgus saruna

U.S. Treasury Yields Close the Week Little Changed -- Market Talk

2025. g. 15. aug. 20:25 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

This Meatpacker Stock Is a Quality Buy at a Discount Price -- Barrons.com

2025. g. 15. aug. 20:24 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

2025. g. 15. aug. 20:18 UTC

Peļņas

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

2025. g. 15. aug. 19:14 UTC

Tirgus saruna

U.S. Natural Gas Settles Higher, But Down on Week -- Market Talk

2025. g. 15. aug. 19:12 UTC

Tirgus saruna

Oil Futures Settle Lower Ahead of U.S.-Russia Summit -- Market Talk

2025. g. 15. aug. 18:32 UTC

Tirgus saruna

Coffee Futures Surge on New Brazilian Frost -- Market Talk

2025. g. 15. aug. 17:33 UTC

Tirgus saruna

U.S. Oil Rig Count Increases By 1 to 412 -- Market Talk

2025. g. 15. aug. 17:23 UTC

Tirgus saruna
Peļņas

Deere's Earnings Appear to Be Troughing -- Market Talk

2025. g. 15. aug. 16:27 UTC

Peļņas

Tariffs Have Rocked e.l.f. Beauty Shares. Why the Fundamentals Still Look Alluring. -- Barrons.com

2025. g. 15. aug. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 15. aug. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 15. aug. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 15. aug. 16:05 UTC

Iegādes, apvienošanās, pārņemšana

Intel's Move Toward Nationalization Won't Work -- at Least for the Long Haul -- Heard on the Street -- WSJ

2025. g. 15. aug. 15:52 UTC

Iegādes, apvienošanās, pārņemšana

What Applied Materials' Poor Outlook Means for Chip Stocks -- Barrons.com

2025. g. 15. aug. 15:36 UTC

Tirgus saruna

Base Metal Prices Mixed; Copper Gains as Focus Shifts to Fundamentals -- Market Talk

2025. g. 15. aug. 15:29 UTC

Peļņas

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

2025. g. 15. aug. 15:29 UTC

Iegādes, apvienošanās, pārņemšana

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

2025. g. 15. aug. 15:28 UTC

Peļņas

JD.com Stock Rises After Earnings Beat. Why Investors Are Relieved. -- Barrons.com

2025. g. 15. aug. 15:24 UTC

Tirgus saruna

Gold Futures Tick Higher But Remain Broadly Rangebound -- Market Talk

2025. g. 15. aug. 15:08 UTC

Tirgus saruna

Applied Materials Is Losing Share in Chips Business -- Market Talk

2025. g. 15. aug. 14:38 UTC

Iegādes, apvienošanās, pārņemšana

African Rainbow Minerals to Own 19.9% of Surge Copper Shares

2025. g. 15. aug. 14:37 UTC

Iegādes, apvienošanās, pārņemšana

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares for C$4.51M

2025. g. 15. aug. 14:37 UTC

Iegādes, apvienošanās, pārņemšana

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares at C$0.175 Each

2025. g. 15. aug. 14:36 UTC

Iegādes, apvienošanās, pārņemšana

African Rainbow Minerals to Acquire Shares of Surge Copper Corp.

2025. g. 15. aug. 14:33 UTC

Iegādes, apvienošanās, pārņemšana

A Trump Intel Stake Could Make National Security the New 'Too Big to Fail' -- Barrons.com

Salīdzinājums

Cenas izmaiņa

AnaptysBio Inc Prognoze

Cenas mērķis

By TipRanks

119.91% augšup

Prognoze 12 mēnešiem

Vidējais 44.29 USD  119.91%

Augstākais 90 USD

Zemākais 19.5 USD

Pamatojoties uz 13 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi AnaptysBio Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

13 ratings

10

Pirkt

2

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

19.25 / 21.135Atbalsts un pretestība

Īstermiņā

Strong Bearish Evidence

Vidējā termiņā

Strong Bullish Evidence

Ilgtermiņā

Neutral Evidence

Noskaņojums

By Acuity

129 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.